A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases

Breast Cancer Research and Treatment

Volumn 82, Issue 3, 2003, Pages 215-222

  Howell, A ^a   Robertson, J F R ^b   Vergote, I ^c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Advanced breast cancer; Anastrozole; Arimidex; Phase III trial; Tamoxifen; Visceral metastases

Indexed keywords

ANASTROZOLE; ANDROGEN; AROMATASE; CYTOCHROME P450; ESTROGEN; FULVESTRANT; HORMONE RECEPTOR; MEGESTROL ACETATE; TAMOXIFEN;

BREAST CANCER; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; VISCERAL METASTASIS;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; NEOPLASM METASTASIS; NITRILES; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; TRIAZOLES;

EID: 0346874444     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BREA.0000004375.17920.0b     Document Type: Review

References (31)

1. Diab SG, Elledge RM, Clark GM: Tumour characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 92: 550-556, 2000
2. Cole MP, Jones CT, Todd ID: A new estrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer 25: 270-275, 1971
3. Miller WR, Stuart M, Sahmoud Y, Dixon JM: Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer. Br J Cancer 87: 950-955, 2002
4. Masamura S, Adlercreutz H, Harvey H: Aromatase inhibitor development for the treatment of breast cancer. Breast Cancer Treat 33: 19-26, 1994
5. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A, Plourde PV: Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 14: 2000-2011, 1996
6. Bonneterre J, Thurlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M, von Euler M: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women - results of the TARGET (Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability) study. J Clin Oncol 18: 3748-3757, 2000
7. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 18: 3758-3767, 2000
8. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thurlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M, Arimidex Writing Committee, Investigators Committee Members: Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma: results of two randomized trials designed for combined analysis. Cancer 92: 2247-2258, 2001
9. Nabholtz JM, Bonneterre J, Budzar A, Robertson JFR, Thürlimann B: Anastrozole (Arimidex™) versus tamoxifen as first-line therapy in hormone-receptor positive advanced breast cancer in postmenopausal women: survival results of two randomized trials designed for combined analysis. Eur J Cancer (submitted)
10. Ellis MJ, Hayes DF, Lippman ME: Diseases of the Breast. 2nd edn, Lippincott Williams & Wilkins, Philadelphia, 2000, pp 749-797
11. Vergote I, Thürlimann B: First-line endocrine therapy in postmenopausal patients with advanced breast cancer and visceral metastases: anastrozole versus tamoxifen. Eur J Cancer 37(Suppl 6): 191, abstract 697, 2001
12. Thürlimann B, Bonneterre J, Budzar A, Nabholtz J-M, Robertson J, Sahmoud T: First-line endocrine therapy in postmenopausal patients with advanced breast cancer and visceral metastases: anastrozole (Arimidex) versus tamoxifen. Proc Am Soc Clin Oncol 20: 1835, 2001 (abstract)
13. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Janicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a Phase III study of the International letrozole breast cancer group. J Clin Oncol 19: 2596-2606, 2001
14. Blanco G, Holli K, Heikkinen M, Kallioniemi OP, Taskinen P: Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading. Br J Cancer 62: 142-146, 1990
15. Clark GM, Sledge Jr GW, Osborne CK, McGuire WL: Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 5: 55-61, 1987
16. Qazi R, Chuang JL, Drobyski W: Estrogen receptors and the pattern of relapse in breast cancer. Arch Int Med 144: 2365-2367, 1984
17. Singhakowinta A, Potter HG, Buroker TR, Samal B, Brooks SC, Vaitkevicius VK: Estrogen receptor and natural course of breast cancer. Ann Surg 183: 84-88, 1976
18. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A: Double-blind randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in post-menopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20: 3386-3395, 2002
19. Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C: Fulvestrant, formerly ICI 182,780 is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20: 3396-3403, 2002
20. Jonat W, Howell A, Blomqvist C, Eiermann W, Winblad G, Tyrrell C, Mauriac L, Roche H, Lundgren S, Hellmund R, Azab M: A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32A: 404-412, 1996
21. Howell A, Buzdar A, Jonat W: Arimidex (anastrozole) -effective in advanced breast cancer (ABC) patients with visceral and liver metastases. Breast Cancer Res Treat 50 Special Issue 304: 434, 1998 (abstract)
22. Mauriac L, Pippen JE, Quaresma Albano J, Gertler SZ, Kent Osbourne C: Fulvestrant (Faslodex®) versus anastrozole for the treatment of advanced breast cancer in a subgroup of postmenopausal women with visceral metastases: combined results from two multicentre trials. Eur J Cancer 39: 1228-1233, 2003
23. Data on file: AstraZeneca, Macclesfield, Cheshire, UK, 2002
24. Kamby C, Rose C: Metastatic pattern and response to endocrine therapy in human breast cancer. Breast Cancer Res Treat 8: 197-204, 1986
25. Perez JE, Machiavelli M, Leone BA, Romero A, Rabinovich MG, Vallejo CT, Bianco A, Rodriguez R, Cuevas MA, Alvarez LA: Bone-only versus visceral-only metastatic pattern in breast cancer: analysis of 150 patients. A GOCS study. Am J Clin Oncol (CCT) 13: 294-298, 1990
26. Falkson G, Gelman R, Falkson CI, Glick J, Harris J: Factors predicting for response, time to treatment failure and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group Study. J Clin Oncol 9: 2153-2161, 1991
27. Rabinovich M, Vallejo C, Bianco A, Perez J, Machiavelli M, Leone B, Romero A, Rodriguez R, Cuevas M, Dansky C: Development and validation of prognostic models in metastatic breast cancer: a GOCS study. Oncology 49: 188-195, 1992
28. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U, Trunet PF: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453-461, 1998
29. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G: Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a Phase III randomized double-blind trial. J Clin Oncol 18: 1399-1411, 2000
30. Jones S, Vogel C, Arkhipov A, Fehrenbacher L, Eisenberg P, Cooper B, Honig S, Polli A, Whaley F, di Salle E, Tiffany J, Consonni A, Miller L: Multicenter, Phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group. J Clin Oncol 17: 3418-3425, 1999
31. Kvinnsland S, Anker G, Dirix LY, Bonneterre J, Prove AM, Wilking N, Lobelle JP, Mariani O, di Salle E, Polli A, Massimini G: High activity and tolerability demonstrated for exemestane in postmenopausal women with advanced breast cancer failing tamoxifen. Eur J Cancer 36: 976-982, 2000